by Lisa Chamoff
, Contributing Reporter | October 18, 2021
From the October 2021 issue of HealthCare Business News magazine
Amidst a global pandemic that continues to challenge healthcare systems, cancer treatment continues to advance.
Manufacturers have integrated real-time imaging into therapy systems and companies such as IBA, IntraOp Medical and Varian continue to research FLASH therapy, which delivers ultra-high doses of radiation in less than a second.
Here's a glimpse at what's new and on the horizon in both proton therapy and radiation therapy.
In April, Hitachi Proton’s system was selected in a public bidding process by Tsukuba University in Japan to build their second proton center, which would begin operations in 2025.
In September 2020, Hitachi received Japanese PMDA approval for an imaging device with dual-CBCT functionality and 4D CBCT capability, available for its PROBEAT proton therapy system.
These new technologies will provide faster and more accurate imaging prior to treatment, said Yui Yoshida, manager of the particle therapy division of Hitachi America.
“Dual-CBCT will enable (clinicians) to take CBCT images with only a 110-degree rotation of (the) gantry, which will save time and contribute to faster treatment workflows,” Yoshida said.
Hitachi already has a real-time image gating system during the treatment. And the 4D CBCT imaging technology will further contribute to image quality by reducing motion effects during patient positioning.
IBA continues to promote, sell, install and maintain its Proteus proton therapy systems to the market. It has sold more than 60 systems worldwide, treating more than 100,000 patients. The next center scheduled to open, in early 2022, for treatment in the U.S. is at University of Kansas Cancer Center.
IBA, its customers and its strategic partners are working together on new clinically relevant technologies.
Among its technology under development is a complete suite of motion management tools to deal with organ motion. The company has several solutions already existing, including beam gating, X-Ray gating and beam repainting. It is currently developing a way to assess interplay effect during the planning phase and a 4D imaging mode that will assess the robustness of the setup before, during or after the treatment delivery.
“Improving the way organ motion is managed should help our customers increase the patients that will qualify for proton therapy,” said Gaelle Coppe, product manager at IBA.
IBA is also developing DynamicARC proton therapy, which delivers spot-scanning proton beam treatments while the gantry is rotating.